Benzydamine HClCAS# 132-69-4 |
- 3,3'-Diindolylmethane
Catalog No.:BCC1306
CAS No.:1968-05-4
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Capsaicin
Catalog No.:BCN1016
CAS No.:404-86-4
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 132-69-4 | SDF | Download SDF |
| PubChem ID | 65464 | Appearance | Powder |
| Formula | C19H24ClN3O | M.Wt | 345.87 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 41 mg/mL (118.54 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine;hydrochloride | ||
| SMILES | CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3.Cl | ||
| Standard InChIKey | HNNIWKQLJSNAEQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H23N3O.ClH/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16;/h3-7,9-12H,8,13-15H2,1-2H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Benzydamine Hcl is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity. References: | |||||
Benzydamine HCl Dilution Calculator
Benzydamine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8913 mL | 14.4563 mL | 28.9126 mL | 57.8252 mL | 72.2815 mL |
| 5 mM | 0.5783 mL | 2.8913 mL | 5.7825 mL | 11.565 mL | 14.4563 mL |
| 10 mM | 0.2891 mL | 1.4456 mL | 2.8913 mL | 5.7825 mL | 7.2281 mL |
| 50 mM | 0.0578 mL | 0.2891 mL | 0.5783 mL | 1.1565 mL | 1.4456 mL |
| 100 mM | 0.0289 mL | 0.1446 mL | 0.2891 mL | 0.5783 mL | 0.7228 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Benzydamine hydrochloride is a topical nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, antipyretic and local anesthetic activity.
- Pheniramine Maleate
Catalog No.:BCC4700
CAS No.:132-20-7
- Diphenylpyraline HCl
Catalog No.:BCC3768
CAS No.:132-18-3
- Benztropine mesylate
Catalog No.:BCC4524
CAS No.:132-17-2
- Shizukaol A
Catalog No.:BCN6984
CAS No.:131984-98-0
- 3,6,19-Trihydroxy-23-oxo-12-ursen-28-oic acid
Catalog No.:BCN1584
CAS No.:131984-82-2
- CC0651
Catalog No.:BCC4200
CAS No.:1319207-44-7
- 1,3,6,8-tetrahydroxy-4-(3-methyl-2-buten-1-yl)-9H-Xanthen-9-one
Catalog No.:BCN1585
CAS No.:1319198-98-5
- Paricalcitol
Catalog No.:BCC1839
CAS No.:131918-61-1
- Solanesol
Catalog No.:BCN2596
CAS No.:13190-97-1
- Goitrin
Catalog No.:BCN2764
CAS No.:13190-34-6
- Fudosteine
Catalog No.:BCC4661
CAS No.:13189-98-5
- 2-Hydroxyethyl Salicylate
Catalog No.:BCN3579
CAS No.:87-28-5
- Dihydrocucurbitacin B
Catalog No.:BCN3118
CAS No.:13201-14-4
- UNC 0646
Catalog No.:BCC2431
CAS No.:1320288-17-2
- UNC 0631
Catalog No.:BCC4143
CAS No.:1320288-19-4
- Cryptoacetalide
Catalog No.:BCN3139
CAS No.:132059-23-5
- Marmesin angelate
Catalog No.:BCN8139
CAS No.:13209-79-5
- Ropivacaine hydrochloride monohydrate
Catalog No.:BCC5169
CAS No.:132112-35-7
- O,O-diacetyldaurisoline
Catalog No.:BCC8221
CAS No.:132139-17-4
- Epi-Cryptoacetalide
Catalog No.:BCN3140
CAS No.:132152-57-9
- Dracoflavan A
Catalog No.:BCN3588
CAS No.:132185-42-3
- 5alpha-Hydroxycostic acid
Catalog No.:BCN6169
CAS No.:132185-83-2
- 5beta-Hydroxycostic acid
Catalog No.:BCN6170
CAS No.:132185-84-3
- (2R,3S)-3-Phenylisoserine hydrochloride
Catalog No.:BCN8527
CAS No.:132201-32-2
Formulation of Bilayer Benzydamine HCl Patch Targeted For Gingivitis.[Pubmed:28127472]
J Drug Deliv. 2016;2016:7598398.
In the present study bilayer patch of Benzydamine HCl was developed using solvent casting method. Different substrates were attempted like Petri dish, glass-and-ring, and teflon-and-ring for selection of the proper option to formulate patch that should give easily peelable film with adequate mechanical properties. HPMC E15 LV was used in different concentrations for obtaining proper viscosity of solution for pouring on to surface and ring, that it should not leak from ring. The second layer was optimized by using different polymer like eudragit RSPO, eudragit RSPO + EC, and eudragit NE30 D for efficient layer bonding. The minimum release from backing membrane was established by diffusion study as compared to from drug loaded layer. The optimized batches were evaluated for folding endurance, weight variation, thickness, drug content, drug release, tensile strength, layer separation, mucoadhesion, moisture uptake, and layer bonding. The novel gingival patch of Benzydamine HCl developed would be beneficial in optimizing the therapy.
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange.[Pubmed:17625955]
Spectrochim Acta A Mol Biomol Spectrosc. 2008 Mar;69(3):770-5.
A simple, rapid and sensitive spectrophotometric method has been proposed for the assay of Benzydamine HCl (BENZ), levamisole HCl (LEV) and mebeverine HCl (MBV) in bulk and pharmaceutical formulations. The method based on the reaction of the selected drugs with methyl orange (MO) in buffered aqueous solution at pH 3.6. The formed yellow ion-pair complexes were extracted with dichloromethane and measured quantitatively with maximum absorption at 422 nm. The analytical parameters and their effects on the reported systems are investigated. The extracts are intensely colored and very stable at room temperature. The calibration graphs were linear over the concentration range of 2-10 microg ml(-1) for BENZ, 6-24 microg ml(-1) for LEV and 4-14 microg ml(-1) for MBV. The stoichiometry of the reaction was found to be 1:1 in all cases and the conditional stability constant (K(f)) of the complexes have been calculated. The proposed method was successfully extended to pharmaceutical preparations-tablets. Excipients used as additive in commercial formulations did not interfere in the analysis. The proposed method can be recommended for quality control and routine analysis where time, cost effectiveness and high specificity of analytical technique are of great importance.
In vitro cytotoxicity of chlorhexidine gluconate, benzydamine-HCl and povidone iodine mouthrinses on human gingival fibroblasts.[Pubmed:11763614]
SADJ. 2001 Oct;56(10):455-60.
Mouthrinses are frequently prescribed for the treatment of ulcerative diseases of the oral mucosa. In this study the in vitro cytotoxic effect of 0.2% chlorhexidine gluconate in water, 0.15% benzydamine-HCl in 8.5% ethanol and 1% povidone iodine in 10% ethanol were determined. Results of photographs and cell counts revealed that all the cells exposed to chlorhexidine gluconate, benzydamine-HCl and povidone iodine were immediately fixated onto the tissue culture surfaces. The three agents were then diluted in phosphate buffered saline to concentrations varying between 10% and 90% and fibroblasts were once again exposed to the dilutions of the test agents. Photographs were taken and cell concentrations in the wells were determined immediately after exposure and after 2, 4 and 24 hours. Results indicated that cells were immediately fixated by 10% chlorhexidine gluconate in water, 20% povidone iodine and 70% benzydamine-HCl. Fibroblasts survived and recovered from the exposure to 8.5% and 10% ethanol, which indicated that the fixation effect is not the result of the ethanol, but should be ascribed to the activity of the active ingredients in the mouthrinses.
Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial.[Pubmed:11550161]
Cancer. 2001 Aug 15;92(4):875-85.
BACKGROUND: Benzydamine was evaluated in patients with head and neck carcinoma for treatment of radiation-induced oral mucositis, a frequent complication of radiation therapy (RT) for which there is no predictable therapy or preventive treatment currently available. METHODS: The safety and efficacy of 0.15% benzydamine oral rinse in preventing or decreasing erythema, ulceration, and pain associated with oral mucositis during RT were evaluated in a randomized, placebo-controlled trial conducted in patients with head and neck carcinoma. Subjects were to rinse with 15 mL for 2 minutes, 4-8 times daily before and during RT, and for 2 weeks after completion of RT; study evaluations were conducted before RT and routinely thereafter up to 3 weeks after RT. RESULTS: During conventional RT, regimens up to cumulative doses of 5000 centigrays (cGy) benzydamine (n = 69) significantly (P = 0.006) reduced erythema and ulceration by approximately 30% compared with the placebo (n = 76); greater than 33% of benzydamine subjects remained ulcer free compared with 18% of placebo subjects (P = 0.037), and benzydamine significantly delayed the use of systemic analgesics compared with placebo (P < 0.05). Benzydamine was not effective in subjects (n = 20) receiving accelerated RT doses (> or = 220 cGy/day). The incidence of adverse events between treatment groups was comparable without significant differences. Early discontinuation because of adverse events occurred in 6% of benzydamine subjects and 5% of placebo subjects, and there was 1 death (related to the primary diagnosis) in a placebo subject. CONCLUSIONS: Benzydamine oral rinse was effective, safe, and well tolerated for prophylactic treatment of radiation-induced oral mucositis.
